United Kingdom (UK)
Recombinant monoclonal antibody to VCAM-1. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 6C7.1.
UniProt Accession Number of Target Protein: P29533
Alternative Name(s) of Target: Vascular cell adhesion protein 1; Vcam1; V-CAM 1; CD106
Immunogen: This antibody was rasied against VCAM-1.
Specificity: This antibody is specific for murine VCAM-1. VCAM-1 is an important in cell-cell recognition. Appears to function in leukocyte-endothelial cell adhesion. Interacts with integrin alpha-4/beta-1 (ITGA4/ITGB1) on leukocytes, and mediates both adhesion and signal transduction. The VCAM1/ITGA4/ITGB1 interaction may play a pathophysiologic role both in immune responses and in leukocyte emigration to sites of inflammation.
Application Notes: The original rat version of this antibody was used to treat experimental autoimmune encephalomyelitis (EAE in female SJL/N mice). It resulted in a later onset of tEAE (Engelhardt et al, 1998; pmid:9854045). To asses α4-integrin–mediated T cell interaction with VCAM-1 on blood-brain barrier–endothelium in experimental autoimmune encephalomyelitis flow cytometry was preformed on T cell blasts labeled with the rat version of this antibody (Vajkoczy et al, 2001; pmid:11518729). Futhermore, PLP-specific T lymphoblasts were used for immunofluorescence with the rat version of this antibody (Vajkoczy et al, 2001; pmid:11518729). And finally, mice were injected with the rat version of this antibody to asses how it can slow down progression of EAE. It showed an ability to slow EAE down (Vajkoczy et al, 2001; pmid:11518729). In research on EAE, T line cells were incubated with the rat version of this antibody. This was then used for flow cytometry (Laschinger and Engelhardt, 200; pmid:10626664). To evaluate vascular luminal VCAM-1 expression in NOD and Blab/c mice the rat version of this antibody was injected in mice after which they were killed and the tissue analyzed (Xu et al, 2003; pmid:12756264). VCAM-1 expression in the dermal and pial microvasculatures was quantified using immunofluorescence with the rat version of this antibody (Norman et al, 2008; pmid:18426970). To investigate the influence of VCAM-1 on tumor progression, the rat version of this antibody was used for blocking of VCAM-1 (Dieterich et al, 2019; pmid:31344266). The rat version of this antibody was also utilized for immunofluorescence on mouse retinal microvascular endothelial cells (Liu et al, 2017; pmid:28931763).
Antibody first published in:
Engelhardt et al. The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin J Clin Invest. 1998 Dec 15;102(12):2096-105. PMID:9854045
Note on publication:
The effects of mAb therapy on the development of EAE in the SJL/N mouse was compared, using a large panel of mAbs directed against alpha4, beta7, the alpha4beta7-heterodimer, and against VCAM-1. Although encephalitogenic T cells express both alpha4-integrins, mAbs directed against the alpha4beta7-heterodimer or against the beta7-subunit did not interfere with the development of EAE.